Listen to Dr Hans Lee sharing his perspective on the phase 3 DETERMINATION TRIAL


Read the publication online in the NEJM

For news on other ASCO 2022 late-breakers covering sarcoma, breast cancer and rectal cancer visit our summary video here

I'm Hans Lee, coming to you from the ASCO 2022 annual meeting in Chicago and I'll be providing my perspective on the late breaking abstract plenary that was just presented of the phase 3 DETERMINATION study.

Now the phase 3 DETERMINATION study really sought to answer a key question of what is the role of upfront high dose melphalan and autologous stem cell rescue in newly diagnosed multiple myeloma patients that receive optimal triplet based induction therapy with bortezomib, lenalidomide and dexamethasone followed by lenalidomide maintenance therapy until disease progression.

The key results of this study demonstrate that there is a significant improvement of progression free survival of approximately 21 months in patients who underwent upfront high dose chemotherapy and autologous stem cell rescue compared to those patients who didn't.

However, at the time that the study is being reported, there was no difference in overall survival between the patients who underwent upfront versus delayed high dose chemotherapy and autologous stem cell rescue.

From my perspective, the data from the DETERMINATION study impact my clinical practice in two main ways.

First, it confirms that upfront high dose chemotherapy and autologous stem cell rescue remains the standard of care in newly diagnosed multiple myeloma patients that receive optimal induction therapy with bortezomib, lenalidomide and dexamethasone.

Secondly, it confirms the role of maintenance lenalidomide after induction therapy until disease progression.

However, without an overall survival benefit seen between those patients who underwent upfront transplant versus those who didn't, it's still important to have a discussion with patients regarding the benefits and risks of autologous stem cell transplant and future analysis from the DETERMINATION study and also the future prospective studies will be very informative to define the right groups of patients that will benefit optimally from upfront stem cell transplant.

Thank you.

Read the publication online in the NEJM

Dr Hans Lee is currently an Assistant Professor and Director of Multiple Myeloma Clinical Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center, where his clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma.   Specifically, his primary research goals are directed towards novel approaches to treating multiple myeloma through early phase investigator-initiated and industry-sponsored clinical trials.

Asst. Prof. Hans Lee has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithSkine, Legend Biotech, Pfizer, Regeneron, Sanofi and Takeda Pharmaceuticals. 

Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LYMPHOMA & MYELOMA CONNECT

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.

Meet the experts

Other programmes of interest

video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
eks
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock MIN
  • calendar Jun 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
conference-update Conference update

Episode

6

of 6

episode
Oncology Hemato-oncology 
Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Episode 6: Lymphoma Update: SWOG S1826 trial

Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager
  • clock 2 MIN
  • calendar Jun 2023

Oncology Hemato-oncology 
Update From ASH 2022

Highlights from the ASH Annual Meeting

Experts
Dr Matthew J. Matasar
  • clock 4 MIN
  • calendar Dec 2022

Educational programme supported by an Independent Educational Grant from COR2ED.
podcast Podcast

Episode

3

of 3

episode
Hemato-oncology 
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin
  • download Downloadable
    Resources
  • clock MIN
  • calendar Mar 2022

Educational programme supported by an Independent Educational Grant from Karyopharm
Hemato-oncology 
Lymphoma Update from ASH 2021

Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL

Experts
Dr Matthew J. Matasar
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2021

Educational programme supported by an Independent Educational Grant from Bayer